New hope for lymphoma patients: experimental drug TORL-5-700 enters human trials
NCT ID NCT07439653
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tests a new drug, TORL-5-700, in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding the safest dose of the drug alone, then testing it in combination with other medicines. About 155 participants will join to see if the drug can shrink tumors and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOLOGICALLY CONFIRMED RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.